Business & Economy
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Source: Business News · Published
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Related stories
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Business News ·
Lucid's Q3 deliveries fall 6.7% as EV maker cuts production to align with demand
Lucid delivered 3,806 EVs and produced 2,954 vehicles during the third quarter. That compared with 4,078 deliveries on production of 3,891 vehicles a year earlier.
Business News ·
US supreme court hears big oil’s bid to block climate damage lawsuits
How court will lean is unclear amid Suncor Energy and ExxonMobil’s attempt to stop lawsuits at state level The US supreme court began its new nine-month term hearing arguments on Monday in a major case in which big oil companies attempted to strike a fatal blow against lawsuits t
Business | The Guardian ·
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
Business News ·
Gatorade maker recalls 122,000 cases of popular sports drink across 37 US states
PepsiCo initiated class II recall of 28oz bottles last month over ‘undeclared’ yellow dyes, FDA notice says About 122,000 cases of the popular sports drink Gatorade have been voluntarily recalled across 37 US states due to their having “undeclared” food dye, according to an offic
Business | The Guardian ·